Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Healthy Community Project

- PMLiVE

AZ claims first-in-class win for Farxiga in heart failure

AZ in pursuit of class leader Jardiance

- PMLiVE

Sanofi patent case win holds off generic rivals for key cancer drug

Boosts hope of increasing future sales

- PMLiVE

The fight for affordable insulin

Activists are organised, and demanding action on US insulin prices - and pointing the finger at pharma

- PMLiVE

Chi-Med cues up two more regulatory filings in cancer

Hong Kong based firm reports strong sales in first marketed product

- PMLiVE

Dupixent drives Sanofi again, but other new drugs are lagging

Reported loss due to restructuring

- PMLiVE

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

One of several anti-CD38 antibodies in pipeline

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Treatment can help patients with advanced disease, companies say

- PMLiVE

M&F Health, 90TEN and Sanofi among big winners at Communiqué Awards

Full results from health comms awards

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Licensed to treat one of the most commonly diagnosed skin cancers

- PMLiVE

FDA clears Dupixent as first-ever drug for chronic rhinosinusitis with nasal polyps

Could add $1bn to revenues, say analysts

MIT reveals new pill to deliver insulin

A new MIT research project, sponsored by Novo Nordisk, is aiming to deliver insulin orally with a pill that releases medicine in the stomach lining. Dina Patel interviews the team...

Blue Latitude Health

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links